Abstract
Introduction
Genome-wide association studies (GWASs) have identified over 200 independent genetic associations with multiple sclerosis (MS) susceptibility. 1, 2 As expected, all variants are relatively common in the population and have modest individual statistical effects on risk. The strongest genome-wide susceptibility locus maps to the major histocompatibility complex (MHC, 6p21.3). This association, which was first described several decades ago, 3, 4 is consistent with the long-held view that MS is fundamentally an antigen-specific autoimmune disease but also reflects the complexity of risk inheritance by harboring multiple statistically independent allelic and haplotypic effects, 5, 6 including protective signals in the class I region 7 and specific class II genes allelic interactions. 2, 8 Recently, the largest meta-analysis of GWASderived data from 47,351 MS subjects and 68,284 controls identified 32 independent associations in the extended MHC including non-classical HLA effects. 2 These new susceptibility variants provide powerful information for understanding the architecture of genetic susceptibility in the MHC region, including gene-gene interactions and may be further investigated to examine their impact on gene function.
The specific association of MS with the class II HLA-DRB1*15:01 allele has been the strongest genetic risk factor and consistently reported for nearly all studies. 9 The most prudent explanation for this observation appears to be related to singularities in the molecular structure of the HLA heterodimer pockets, namely the large predominantly hydrophobic P4 pocket of the peptide-binding domain of HLA-DRß1*15:01, determining peptide ligands specificity and composition of the responding T-cell receptor repertoire. 10 For the putative MS autoantigen myelin basic protein (MBP), this P4 pocket may be occupied by the aromatic side chain Phe92, responsible for its high-affinity binding to the HLA-DRα01:01/HLA-DRß15:01 heterodimer. The presence of alanine at the polymorphic HLA-DRβ71 position is critical in creating the necessary space for Phe92 of MBP, and among the common HLA-DRB1 alleles, the uncharged Ala at this position is only observed in the HLA-DRB1*15 allele group (HLA-DRB1*15:01-HLA-DRB1*15:06).
HLA-DRB1*15 allelic variants are in strong linkage disequilibrium (LD) with a second functional DRB locus of restricted polymorphism, HLA-DRB5. Remarkably, the crystal structure of an HLA-DRα/ HLA-DRß5*01:01-Epstein-Barr virus peptide complex revealed a striking structural similarity to the HLA-DRß1*15:01-MBP peptide complex at the surface presented for T-cell receptor recognition, 11 suggesting that peptides with only limited sequence identity with a myelin peptide could activate autoreactive T-cells. Not surprisingly, HLA-DRαHLA-DRß5 heterodimers appear to be effective MBP antigen-presenting molecules. 12, 13 In addition, HLA-DRB5*01:01-humanized transgenic mice crossed with mice expressing T-cell receptors specific for MBP 83-99 showed spontaneous experimental autoimmune encephalitis (EAE). 14 Of great interest is the report of HLA-DRB1~HLA-DRB5 epistatic functional interactions elegantly shown in an HLA-humanized EAE model, whereby HLA-DRB1 alleles underlie susceptibility and severity is mediated by HLA-DRB5. 15 The prediction derived from the murine model that HLA-DRB5 acted as a modifier, was confirmed in HLA-DRB5-null African-American MS patients, showing a faster progression to the progressive phase of the disease. 16 However, the full spectrum of HLA-DRB5 coding and non-coding variation in the context of MS susceptibility is unknown.
HLA-DRB1*04 has been reported to be associated with MS disease susceptibility, 17, 18 but this correlation appears to be limited by the ancestry of the population. In contrast to HLA-DRB1*15:01 that is associated with MS risk regardless of the clinical phenotype, carriage of HLA-DRB1*04 alleles has also been shown to be associated with the development of primary progressive disease MS (PP-MS) course. 19 However, this observation was not found consistently and several other studies could only either suggest a non-significant trend to a positive association of HLA-DRB1*04 alleles with PP-MS 20 or no effect at all. 21 On the other hand, a few studies have shown a protective effect of HLA-DRB1*04 with MS. 22, 23 The major limitation of previous studies, examining HLA-DRB1*04 with MS, is that most HLA-DRB1*04 genotypes are ambiguous due to serological or molecular low "first-field" resolution typing. The DR4 serotype represents a large heterogeneous group of more than 300 HLA-DRB1*04 alleles, many of which have substantially different amino acid sequences forming the antigen-binding site of the HLA molecules. Definitive HLA-DRB1*04 alleles were not assigned in many of the previous studies, and therefore it is very likely that different HLA-DRB1*04 alleles, as well as the disease heterogeneity of the patients studied, may have been responsible for the opposing effects on MS risk and outcome. In addition, HLA-DRB1*04 alleles have various predisposing effects in rheumatoid arthritis (RA), suggesting balance in autoimmune effects of ancestral haplotypes; this concept should also be considered in the study of MS.
The application of next-generation sequencing (NGS) to the study of highly polymorphic and structurally complex regions of the human genome increases the throughput, accuracy, and resolution of genetic analysis by several orders of magnitude, presenting an opportunity to better understand the biological mechanisms underlying HLA disease associations. Many studies of HLA disease association have imputed HLA alleles from single-nucleotide polymorphism (SNP) typing. 1 
Materials and methods

Study population
The dataset consisted of 2828 de-identified DNA samples from 1403 MS patients (1016 females, 72.4%) and 1425 healthy unrelated controls (791 females, 55.5%). All MS subjects met established diagnostic criteria 24 and are non-Hispanic white. Control subjects were also white of European ancestry and reported no self-history of personal chronic diseases or in their nuclear family. This study was approved by the University of California, San Francisco Institutional Review Board.
HLA genotyping DNA samples were retrospectively typed for HLA class II loci (HLA-DQB1, HLA-DQA1, HLA-DRB1, HLA-DRB4, and HLA-DRB5) using the MIA FORA NGS high-throughput semi-automated typing protocol (Immucor, Inc., Norcross, GA) and performed as per the manufacturer's instructions. The coverage for class II loci amplified by long-range polymerase chain reaction (PCR) are: HLA-DQB1 5′UTR to 3′UTR; HLA-DQA1 5′UTR to 3′UTR; HLA-DRB1/4/5 gene fragments were amplified in two separate reactions, 5′ UTR to the first ~270 bp of intron-1 and ~250 bp at the 3′ end of intron-1 to exon-6. Sample libraries were prepared and sequenced at a final concentration of 12 pM spiked with 5% PhiX on the Illumina HiSeq-2500 or 1.3 pM with 2% PhiX on NextSeq-500 instruments using 150 cycle paired-end kits (Illumina, Inc., San Diego, CA).
HLA sequence data analysis and genotype assignment NGS sequence data stored as FASTQ files were uploaded into the MIA FORA FLEX v3.0 alignment software (Immucor) for analyses and assignment of HLA genotypes. The MIA FORA software demultiplexes FASTQ files according to each unique index and uses two complementary informatic strategies; competitive mapping of paired-end sequence reads and de novo assembly of paired-end reads to construct one-or two-phased consensus sequences. Paired-end reads and consensus sequences are compared with three sources of HLA reference sequences: (a) the IPD-IMGT/HLA database v3.25.0 (https://www.ebi. ac.uk/ipd/imgt/hla/), (b) internal MIA FORA HLA references generated by cloning with sequencing, and (c) computational filled in silico HLA sequences, to assign genotypes. Final correct HLA genotype calls were assigned after manual review.
Short tandem repeat ambiguous groups
The MIA FORA software permits detailed examination of all sequence segments, as well as unambiguous allele assignment, with the exception of short tandem repeat (STR) enriched regions located within introns of some class II genes. These STR regions consists of "A" or "T" mononucleotides and/or "GT" and "GA" dinucleotides that are repeated typically ~10 to ⩾20 times and cannot be assessed accurately by the sequencing methodology. Allele groups that are indistinguishable due to STRs are given the suffix SG (STR group) to the lowest numbered allele in that group. Characteristics of STRs for each SG and ambiguities that occur due to unsequenced regions within the HLA genes are described in Supplementary Table 1 .
DRB5 reference sequences
There are two HLA-DRB5*01:01:01 genomic reference sequences included in the MIA FORA HLA software; HLA-DRB5*01:01:01 (GenBank accession number AL713966) and an intronic variant of HLA-DRB5*01:01:01 but lacking intron-1 sequence, denoted as HLA-DRB5*01:01:01v1_STR1 (#KU593576) that was generated by cloning and sequencing experiments (Barsakis et al. manuscript in preparation). Genomic sequences for both alleles are located in the European Nucleotide Archive repository (https:// www.ebi.ac.uk/ena).
Statistical analyses
Allele carrier frequencies were determined by direct counting and were calculated as the number of individuals carrying a specific allele (either at the homozygous or heterozygous state) divided by the total number of individuals. In control subjects, allele frequencies at all loci were tested for deviations from Hardy-Weinberg equilibrium (HWE) proportions using the exact method of Guo and Thompson implemented in the PyPop software. 25 The BIGDAWG software 26 was used to estimate six locus haplotypes. The effect sizes of HLA alleles, HLA-DRB1*04:01-and HLA-DRB1*15:01-bearing haplotypes on MS risk were measured by odds ratio (OR) with 95% confidence intervals (CIs), and associated probability (p) values derived from a two-tailed Fischer's exact test. A p value of 0.05 (α) or less was considered statistically significant. Statistical analyses were performed using the R statistical program v3.3.2. Power calculations were performed using the PS power-calculator program 27 (Supplementary Table 2) .
Results
Allele-level association analyses
We tested in this population HLA-DRB1*04, HLA-DRB1*15, and HLA-DRB5*01 for allelic heterogeneity and susceptibility to MS risk. Analyses of HLA NGS data from MS patients and controls revealed no new deleterious mutations that could affect expression in any of the alleles detected. The levels of discrimination by the NGS method and testing multiple loci were able to estimate accurately the OR for susceptibility and resistance of alleles and haplotypes compared to low-resolution typing methods (PCR sequence-specific oligonucleotide probe (PCR-SSOP) and sequence specific primer (SSP)) or imputations of HLA alleles. The distribution of allele frequencies at all loci in controls did not deviate significantly from HWE. Allele frequencies were compared in the MS cases and controls ( Table 2) . Of the overall 17 HLA-DRB1*15:01-bearing haplotypes observed in the dataset, 11 different haplotypes were found in both MS patients and control subjects, whereas 2 haplotypes, which are HLA-DRB5*01: (Table  4) 
Discussion
In this study, we performed high-resolution NGS typing of the HLA class II genes, HLA-DQB1, HLA-DQA1, HLA-DRB1, HLA-DRB4, and HLA-DRB5 to refine our current understanding of the effect of HLA alleles and haplotypes on MS susceptibility and protection in the European-American population. We exploited the powerful combination of long-range PCR (amplification of the entire locus or wide coverage of key regions of the gene) with NGS to generate accurate non-ambiguous 6-to 8-digit HLA genotypes. These "ultra" high-resolution genotypes represent a more detailed description of HLA allelic variants, differing in coding and non-coding gene segments, than 2-or 4-digit typing. Furthermore, differences in intronic polymorphisms is useful for breaking down MHC LD patterns, which may be pertinent for locating the casual variant(s) in disease association studies.
Specifically, we focused our investigation on HLA-DRB5*01~HLA-DRB1*15:01~HLA-DQA1~HLA-DQB1 and HLA-DRB4*01~HLA-DRB1*04:01~ HLA-DQA1~HLA-DQB1 alleles and haplotypes. We have confirmed the numerous previous findings of a strong association of HLA-DRB1*15:01 with MS susceptibility especially in white populations such as European-Americans, 28, 29 and groups from Europe 30 and Australia. 23, 31 In addition, the allele frequency of HLA-DRB1*15:01:01:01SG in MS cases (50.5%) and the strength of association (OR = 3.20) found in our study is similar to those reported in other white datasets. [29] [30] [31] The HLA-DRB1*15:01 MS association have also been found in non-European populations such as African-Americans, 16 Latin-Americans, 32 and Chinese cohorts, 33 but the strength of association was weaker than reported in European ancestry populations, also other class II alleles were found to be of greater effect than HLA-DRB1 35 In some diseases such as RA, where specific motifs that determine function appear to have causative effects, the application of NGS extended testing may allow for fine mapping of these factors. In the present study, because of tight LD, we were unable to map these structural features to only one allele of a given locus, lending the contribution of different factors in several steps of the disease causing mechanism, such as peptide presentation and elimination of T-cell clones in the thymus.
HLA class I and II alleles exist on extended haplotypes encompassing multiple genes and specific alleles in tight LD; therefore, it is possible that different loci and alleles act in synergy to confer susceptibility or protection to MS risk. Compared to the number of class II loci implicated in MS, a few class I alleles have been reported to be associated with susceptibility to MS (HLA-A*03, HLA-B*07), independent of class II molecules, and the class I protective effect has been reported to be mainly driven by HLA-A*02:01 30 and HLA-B*44:02 (Bw4-80 T). 29 One of the protective HLA-DRB1*04:01:01:01SG extended haplotypes found in this study includes the HLA-B*44:02 allele. The mapping of protection may be elucidated when both class I and II HLA loci are examined simultaneously by ultra-high-resolution typing. The NGS approach taken in the present study can be applied to examine systematically the effect of all classical class I and class II HLA alleles in diseases in which associations with HLA factors have been described. In conclusion, our results support and extend previous findings of an association between HLA-DRB1*15:01 and HLA-DRB1*04:01 alleles with MS and demonstrate the advantages of high-resolution NGS to determine risk and protective haplotypes. Larger multi-ancestral studies using NGS combined with genotyping of a dense set of SNP markers are planned to further elucidate the contribution of HLA to MS susceptibility.
